Introduction
A growing body of empirical and experiential evidence indicates that certain individuals can develop maladaptive patterns of consuming behaviors and substances that are essential for survival, including food and sex [1 ] . This paper will review current, and proposed, definitions of substance use disorders, recent advances in our understanding of the physiology of addiction and food consumption, newly published evidence of food addiction, freshly developed tools to better characterize pathological appetitive behaviors, and pharmacological treatments for obesity currently under development.
Defining substance use disorders
The fifth edition of the Diagnostic Statistical Manual (DSM-V), set to be released this year, includes a number of revisions to the types and definitions of substancerelated disorders that were recognized in the DSM-IV. The DSM-V does away with the DSM-IV's catchall diagnosis of 'substance dependence', and replaces it with the diagnosis of 'substance-use' disorder. A substance-use disorder, as the DSM-V will define it, is 'A maladaptive pattern of substance-use leading to clinically significant impairment or distress, as manifested by two (or more) of the listed criteria occurring within a 12-month period (see Table 1 ) (http://www.dsm5.org/ProposedRevisions/Pages/ Substance-RelatedDisorders.aspx) '. Also included will be severity, course, and physiological specifiers. These revisions will better align diagnostic definitions with widely accepted, evidence-based theories about the behavioral and physiological progression of substanceuse disorders. Indeed, addiction, which is a chronic and relapsing illness, lies on one end of a continuum of maladaptive patterns of substance use. Although some individuals never progress beyond experimentation, others advance to regular drug use, drug abuse, drug dependence, or all [1 ] . This pathologic progression of substance use is characterized by 'preoccupation; escalation; tolerance; denial; a series of medical, psychological, and social consequences related directly to the continued use; and what has been referred to as a 'fatal attraction' between the substance (or activity, e.g., gambling) and the patient (p. 42) [1 ] '.
Addiction progresses through three distinct stages, each with a defining sign or symptom: bingeing is the signature attribute of stage 1, withdrawal is the cardinal feature of stage 2, and substance cravings characterize stage 3 [2]. Cross-sensitization, defined as the enhanced response to use of a new substance that results from prior use of a different drug, also suggests vulnerability to addiction [2] . Stress can also predispose to addiction and to relapse.
The neurobiology of addiction
Drug addiction results from the usurping of neurobiological pathways that are involved in, and help to regulate, reward, motivation, decision-making, learning, and memory [3 ] . More simply, drugs of abuse 'hijack' these neural systems, hindering them from carrying out their normal physiological roles and forcing them to become responsive to the drug of abuse. Drug-seeking behavior is motivated and reinforced not only by a drug's positive effects -the 'high' associated with drug use -but also the negative state or 'antireward' that accompanies abstinence from drug use [4] . Different neural networks mediate each of these forces. Indeed, dopaminergic, gabaergic, opioid, and serotonergic neural circuits in the striatum, amygdala, orbitofrontal cortex (OFC), and midbrain are the primary drivers of the feelings of pleasure and reward that flow from drug use [4] . The irritability, anhedonia, and dearth of motivation for natural rewards that characterize the state of antireward result not only from the loss of function of the brain's reward systems but also from the activation of stress systems in the amygdala [4] .
Although all drugs of abuse activate dopamine pathways, stimulants -including cocaine and amphetaminesactivate this system to the most extreme degree, and dopamine appears to be the primary mediator of stimulant dependence. In contrast, ethanol, opioids, and nicotine appear to exert their acute reinforcing effects predominately through activation of opioid receptors [2].
Ultimately, however, dopamine appears to be the predominate mediator of addiction. Evidence of de-novo gambling, eating, and sexual addictions in patients with Parkinson's disease is, perhaps, one of the most persuasive examples of dopamine's potent ability to influence consumptive behaviors. Patients with Parkinson's disease -a disease characterized by deficiencies in dopaminergic neurotransmission, and which is associated with very low rates of substance abuse, and with a personality type that 'is the polar opposite of the addictive personality (p. 502)' -can become addicted to the dopamine supplements that are used to treat this disease, or develop behavioral addictions [5 ] .
Physiology of food consumption
Both central neuronal circuits and peripheral signaling systems help to regulate food consumption [3 ] . Four brain regions appear to be involved in the regulation of feeding: the amygdala/hippocampus, insula, OFC, and the stratium [6 ] . Together, these neural circuits assist with 'learning about (food) rewards, allocating attention and effort toward (food) rewards, setting the incentive value of stimuli in the environment, and integrating 360 Genes and cell metabolism Recurrent substance use in situations in which it is physically hazardous (e.g., driving an automobile or operating a machine when impaired by substance use) 3.
Continued substance use despite having persistent or recurrent social or interpersonal problems caused or exacerbated by the effects of the substance (e.g., arguments with spouse about consequences of intoxication and physical fights) 4.
Tolerance, as defined by either of the following: (a) Need for markedly increased amounts of the substance to achieve intoxication or desired effect (b) Markedly diminished effect with continued use of the same amount of the substance (Note: tolerance is not counted for those taking medications under medical supervision such as analgesics, antidepressants, ant-anxiety medications, or beta-blockers) 5.
Withdrawal, as manifested by either of the following: (a) The characteristic withdrawal syndrome for the substance (refer to Criteria A and B of the criteria sets for withdrawal from the specific substances) (b) The same (or a closely related) substance is taken to relieve or avoid withdrawal symptoms (Note: withdrawal is not counted for those taking medications under medical supervision such as analgesics, antidepressants, antianxiety medications, or beta-blockers) 6.
The substance is often taken in larger amounts or over a longer period than was intended 7.
There is a persistent desire or unsuccessful efforts to cut down or control substance use 8.
A great deal of time is spent on activities necessary to obtain the substance, use the substance, or recover from its effects 9.
Important social, occupational, or recreational activities are given up or reduced because of substance use 10. The substance use is continued despite knowledge of having a persistent or recurrent physical or psychological problem that is likely to have been caused or exacerbated by the substance 11. Craving or a strong desire or urge to use a specific substance homeostatic information about energy stores and gut contents with information about the outside world such as the availability of food (p. S30) [6 ] '. Dopaminergic 'reward' pathways in the midbrain are responsible not only for motivating food consumption but also for the pleasurable feelings that eating produces [3 ,6 ] . Dopaminergic systems project throughout the brain and interact with opioid-mediated gabaergic, cholinergic, and serotonergic circuits. These circuits are essential for survival, precisely because they drive and reinforce behaviors that promote energy intake. The hypothalamus and the arcuate nucleus have been implicated in weight regulation [3 ] . Orexin and melanin play important signaling roles in hypothalamic circuits, whereas neuropeptide Y and alpha-melanocyte-stimulating hormone figure prominently in neural signaling in the arcuate nucleus [3 ] .
Four gut and fat-derived hormones -ghrelin, leptin, insulin, and peptide YY -facilitate the homeostatic regulation of feeding by providing critical feedback to the brain about hunger, satiety, and energy needs [3 ] . Ghrelin (the 'hunger peptide') is released from the stomach and acts on the hypothalamus to raise food consumption [3 ] . Serum ghrelin levels typically rise during a fast and fall after feeding. Leptin relays information to the brain about the body's fat reserves. This hormone acts on the hypothalamus to decrease food intake and increase metabolic rate, and thus plays a critical role in maintaining long-term energy homeostasis [3 ] . Insulin and peptide YY, from the pancreas and small intestine, respectively, relay to the brain information about acute changes in energy levels.
These central and peripheral signaling pathways are highly interconnected. Ghrelin stimulates dopaminergic reward pathways, whereas leptin and insulin inhibit these circuits. Moreover, signaling circuits in both the hypothalamus and the arcuate nucleus receive peripheral signals and project to other regions of the brain, including midbrain dopaminergic centers [3 ] . Importantly, these midbrain dopaminergic circuits also modulate 'survivalrelated' activities, including feeding and sex [1 ,3 ] .
New insights into the physiology of food consumption and abuse
Recent research on the drivers of alcohol and fat consumption suggest that both alcohol and fat intake lead to the production of hypothalamic orexigenic peptides, which not only stimulate increased consumption of these substances but also mediate elevations in circulating triglycerides. First, Barson et al. [7] and Karatayev et al. [8] have demonstrated that, in rats, alcohol use leads to increased consumption of fatty foods and vice versa. Second, alcohol and fat appear to have a direct and synergistic effect on increasing serum triglyceride levels. Third, administering gemfibrozil to rats on a high-fat diet lowered serum triglycerides, levels of hypothalamic orexigenic peptides, and subsequent alcohol intake. Furthermore, mice overexpressing the orexigenic peptide galanin exhibit a greater preference for fatty foods and alcohol than do wild-type rats [8] . In another study using rats Karatayev et al. [9] found that after a high-fat meal, the circulating triglycerides were a predictor of increased caloric intake and orexigenic peptide expression.
Evidence of food addiction from animal studies
Avena et al. [10 ] have developed a rat model of binge eating on sugar and sugar/fat solutions. They have shown that rats provided with 2 h of access to a sugar/fat solution will consume the majority of their daily energy intake during this window, despite having continuous access to normal laboratory chow [10 ] . Moreover, sugar-bingeing rats consume more sugar solution over time (evidence of tolerance), demonstrate increased sugar consumption after a period of abstinence (deprivation effect), and exhibit signs of opiate-like withdrawal, including 'teeth chattering, forepaw tremor, and head shakes (p. 625)' when given a high dose of naloxone, an opioid antagonist [10 ] . Sugar-bingeing rats become cross-sensitized to both amphetamines -which has no effect on naive ratsand cocaine.
Sugar bingeing, like drug abuse, consistently stimulates dopamine release in the nucleus accumbens (NAc) [10 ] . After 4 weeks on a high-fat diet, mice demonstrated large increases in NAc levels of deltaFosB, a molecule that both enhances many drugs' rewarding properties and drives users to acquire them [11 ] .
Geiger et al. [12 ] showed that rats that became obese on a cafeteria-style diet exhibit lower baseline levels of mesolimbic dopamine activity than normal-weight rats fed a standard chow diet. Furthermore, although a cafeteria meal stimulated dopaminergic activity in the obese cohort, a challenge with normal rat chow did not [12 ] . The implication is that obese rats' abuse of palatable food depressed baseline levels of extracellular dopamine, which in turn led them to rely on palatable food consumption to increase dopamine release [12 ] . These findings suggest that the rats developed a dopaminemediated addiction to palatable food. Mathes et al.
[13 ] recently showed that mice bred to exercise excessively had significantly higher concentrations of dopamine in the dorsal striatum and NAc than did mice bred for obesity and controls. Additionally, they found large differences in dopamine gene expression between the high-exercise and obese mice on the one hand and control mice on the other hand. These results highlight the critical role that dopaminergic pathways play in regulating both consumptive behaviors and activity levels, and suggest that common alterations in these pathways may underlie overeating and excessive exercise [13 ] . Although dopamine's role in controlling appetitive behavior is fairly well established, current work has begun to advance our understanding of how other signaling channels -including muscarinic and serotonergic pathways -modulate food consumption. For example, Perry et al. [14 ] demonstrated that intra-NAc cholinergic blockade significantly reduced food consumption in fooddeprived rats, but had no effect on water intake. Moreover, Pratt et al. [15] showed that selective stimulation of different serotonergic receptors subtypes in the NAc of living rats resulted in distinct changes in the rats' feeding behaviors. For example, although intra-NAc infusion of a 5-hydroxytryptamine (5-HT) 1/7 receptor agonist led to a dose-dependent reduction in rats' consumption of both laboratory chow and a highly palatable food/sucrose solution, selective stimulation of NAc 5-HT6 receptors resulted in a dose-dependent rise in food consumption [15] .
Imaging evidence of food addiction
Functional MRI (fMRI) imaging studies in humans demonstrate that food and drug cues activate the same regions of the brain -the amygdale, insula, OFC, and striatum (of course, only addicts' brains are responsive to drug cues) [6 ,16 ] . Additionally, food cravings also lead to changes in fMRI signals in the hippocampus, insula, and caudate, brain areas that are involved in drug cravings, and in the integration of memory with sensory information [16 ] . Drug cravings can activate cortical and limbic regions of the brain, which regulate selfcontrol, motivation, and memory. Interestingly, these same areas of the brain become activated in obese individuals in response to gastric stimulation [3 ] .
Like drug addicts, obese individuals exhibit decreased striatal D2 receptor availability and demonstrate elevated levels of metabolism in the somatosensory cortex, suggesting 'an enhanced sensitivity to the sensory properties of food (p. 8) [3 ]'. Taken together, these findings indicate that the brains of obese individuals may change in ways which not only reinforce food consumption but which also impair their ability to derive pleasure from activities other than eating [3 ] .
New clinical and behavioral evidence of food addiction in humans
Certain pathologic patterns of food consumptionparticularly consistent overeating, binge eating, stressinduced eating, and emotional eating -bear a striking resemblance to substance-use disorders [17 ,18] . Studies of women who report carbohydrate cravings have found that carbohydrates 'seem to have an almost medicinal value in women who crave them (p. 2) [17 ]'. Over time, women who crave carbohydrates develop an increased preference for this type of food ('liking', or sensitization) and tolerance to the food's ability to ameliorate dysphoria. These findings support the conclusion that carbohydrates have abuse potential [17 ] .
People can also learn to associate food consumption with external cues -including advertisements, sights, smells, and sounds. Once made, these associations, or external food sensitivities, can trigger food cravings, overeating, and an increased preference for highly palatable foods [17 ] . Furthermore, the majority of people consume more food when stressed, and demonstrate a preference for high-fat or high-carbohydrate foods [5 ] . Stress also predisposes drug addicts to relapse, and is a 'significant cause of failure in dieters (p. S31) [6 ] '.
As evidence of food addiction has mounted, experts have proposed new explanations for how and why this illness has evolved. For example, Ifland et al. [18] hypothesized that humans can become addicted to refined foods (the 'refined food hypothesis'), which contain processed sugars, fat, salt, flour, caffeine, or all, but not to unrefined foods. Building on evidence that opiate addicts consume increased amounts of salted foods and gain weight while withdrawing, Cocores and Gold [19 ] proposed that salt is a mild opiate agonist.
Gender differences in appetitive behavior
Recent works by Wang et al. ] demonstrated that the 'presentation of appetitive stimuli to fasting individuals increased self-reports of hunger and desire for food and increased whole brain metabolism to a similar (p 1251)' degree in both sexes. Furthermore, both men and women reported decreased hunger and desire for food during deliberate cognitive inhibition of their wish to eat. However, although mens' brains demonstrated reduced activity in limbic and paralimbic areas during cognitive inhibition, womens' brains showed no change in metabolic activity during this exercise [20 ] . These findings suggest that the brains of men and women respond differently to efforts to control or regulate appetitive behaviors. Cornier et al.
[21 ] reported a number of sex-based differences in consumptive behavior. First, during ad-libitum feeding, men were more prone to overeating, whereas women tended to match caloric intake with energy expenditure. Second, women reported higher postprandial satiety than did men. Third, Cornier et al.
[21 ] noticed significant sex-based differences in neuronal activation in response to visual food stimuli. Women in Cornier et al.
[21 ]'s study were able to control their consumptive behaviors more effectively than men, and demonstrated a greater prefrontal and parietal response to visual food stimuli than did men [21 ] . The results of these two studies not only suggest that sex-based differences in appetitive behavior may help to explain disparate rates of obesity in men and women but also indicate that more work is needed to better characterize them.
Genetic and environmental influence
The genetic and environmental influences on the risk of becoming overweight or obese are substantial and could not be adequately treated within the scope of this review. We know that the intrauterine environment may significantly impact a child's subsequent risk of developing obesity, diabetes, and hypercholesterolemia and new research indicates that exercise may decrease the effects of genetic influence in adolescents. For those interested in exploring this area further, we direct you to these references [22,23,24 ,25,26 ,27 ].
Assessing for pathological eating patterns: new developments
Gearhardt et al.
[28 ] created the Yale Food Addiction Scale (YFAS), a series of questions designed to identify and better characterize signs and symptoms consistent with food addiction. In early testing, the YFAS 'exhibited adequate internal reliability, . . . good convergent validity with other measures of eating problems, and good discriminant validity relative to related but dissimilar constructs such as alcohol consumption and impulsivity (p. 4) [28 ]'. As the authors recognize, the YFAS may not only help clinicians to better identify food-use disorders in their patients but may also help researchers to identify potential candidates to recruit for future studies in this area [28 ] .
New pharmacological treatments for obesity
A number of pharmacological treatments derived from addiction models for obesity are either under development or in clinical trials (see Table 2 ). Three drugs are currently in phase III clinical trials: Contrave (Orexigen Therapeutics, Inc., La Jolla, California, USA), Qnexa (Vivus Inc., Mountain View, California, USA), and Lorcaserin (Arena Pharmaceuticals, Inc., San Diego, California, USA) [29, 30] . Many of these drugs have significant sideeffects. For example, Lorcaserin can cause or increase symptoms of depression, anxiety, and obsessive-compulsive disorder (OCD) via inhibiting release of brain dopamine. In addition, bupropion (an element of Contrave) lowers seizure thresholds and topiramate (a component in Qnexa) has been associated with an increased risk of suicide, confusion, and memory deficits. Most of these treatments target pathways that have been discussed in this review, and which play critical roles in addiction. Importantly, experts anticipate that they will receive US Food and Drug Administration approval [29] . The organismic salience of these brain messengers has made psychopharmacological treatment developments for drug abuse and dependence slow and challenging. We may expect addiction-targeted antiobesity treatments to have a great risk of causing important mood and other side-effects, which will need to be carefully considered by the prescribing physician and closely monitored.
Areas for further study
To date, research in animals has focused on the hedonic properties of sugar and fat. However, we know less about the rewarding or addictive properties of salt. More research is also needed to better understand the degree to which salt, sugar, and fat act synergistically to motivate hedonic eating. Investigations into the gut-brain interactions [31] and hormone-dopamine [32] addictive properties of other types of ingredients -particularly those found in processed or energy-dense foods -are warranted as well.
Conclusion
Understanding the forces that sustain hedonic eating is essential to developing and implementing treatment and management strategies that address the root causes of the obesity epidemic. Neurobiological advances in modeling tobacco smoking, alcohol, and other drug addictions have
Neurobiology of food addiction Blumenthal and Gold 363 enabled clinical scientists to study the brain systems of interest in humans. PET and fMRI studies have been conducted for decades, detailing the changes that routinely occur in human addicts and providing neurobiological insights that have changed physician acceptance of the importance of brain change in the addiction process. Public health and treatment professionals, once tobacco addiction was accepted, could develop legal and taxation strategies aimed at delaying use, decreasing harm, and protection from second and third-hand exposure. Treatment professionals used these new insights to provide replacement, detoxify, and develop an entirely new class of anticraving and relapsing medications. Basic neuroscience studies, building on addiction neuroscience models, have demonstrated avid self-administration of glucose, fructose, and junk food [33 ] in laboratory animals with corresponding changes in addiction-relevant neurotransmitters and systems. Human neuroimaging studies, also using methods developed over decades of studying human alcoholics and addicts, have suggested that hedonic food can act like a traditional drug of abuse, causing brain changes almost indistinguishable from those produced by drugs. Studies have shown somatosensory cortex and other neurobiolgical changes that make losing weight much more difficult. In the absence of consistently effective lifestyle or pharmacological interventions that address these root causes, families are increasingly turning to invasive and expensive bariatric surgical treatments, including gastric bypass and gastric banding, to help themselves and their children lose weight. These procedures can yield dramatic weight loss, but also have significant, well known, and potential sideeffects. Furthermore, 'psychosocial outcomes after weight loss surgery (WLS) have not been adequately studied, particularly in adolescents (p. 906) [34] '.
Obesity and its attendant complications place a tremendous and ever increasing burden on healthcare systems. Recent research on the neurobiological systems that motivate appetitive behavior strongly suggests that an acquired drive for highly energy-dense, reinforcing foods is contributing to the obesity epidemic. The limitations of current treatments compel healthcare professionals to develop more effective ways based on neurobiological addiction models to curb the obesity epidemic.
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